Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
Abstract Background Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we eval...
Main Authors: | Christina Jensen, Daniel Hargbøl Madsen, Morten Hansen, Henrik Schmidt, Inge Marie Svane, Morten Asser Karsdal, Nicholas Willumsen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0474-z |
Similar Items
-
Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade
by: Christina Jensen, et al.
Published: (2020-09-01) -
36 Degradation of type III and IV collagen associates with outcome when measured in serum from patients with metastatic melanoma treated with immune checkpoint inhibitors
by: Marco Donia, et al.
Published: (2023-11-01) -
Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01) -
Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
by: Kalijn Fredrike Bol, et al.
Published: (2019-10-01) -
Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy
by: Christina Jensen, et al.
Published: (2021-10-01)